CalciMedica, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $15.2M | $14.5M | $15.9M | $8.4M | $18.9M | $21.0M | $30.6M |
| SG&A Expense | — | $7.9M | $9.7M | $22.2M | $5.8M | $17.0M | $8.9M | $6.9M |
| Operating Income | — | $-23.1M | $-24.2M | $-38.1M | $-14.2M | $-35.9M | $-29.8M | $-37.5M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-29.6M | $-13.7M | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $1.0K | $1.0K | — | — | — |
| Net Income | — | $-29.6M | $-13.7M | $-34.4M | $-7.8M | $-35.8M | $-27.5M | $-37.0M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.97 | $-1.22 | $-2.55 | $-37.05 | $-0.56 | $-1.75 | $-11.14 |
| EPS (Diluted) | — | $-1.97 | $-1.22 | $-2.55 | $-37.05 | $-0.56 | $-1.75 | $-11.14 |
| Shares Outstanding (Basic) | 15.7M | 15.0M | 11.2M | 13.5M | 64.5M | 63.6M | 62.9M | 4.1M |
| Shares Outstanding (Diluted) | 15.7M | 15.0M | 11.2M | 13.5M | 64.5M | 63.6M | 62.9M | 4.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |